Loading drug development pipeline…
Loading drug development pipeline…
Derived
For each drug, the most advanced stage supported by registered interventional trials and jurisdiction-aware approval records. Approval in any ingested jurisdiction outranks trial phase; a drug is counted once, at its highest stage.
Computedci-drug-pipeline-v1Stage rulesApprovals feed →
Funnel
Drugs reach Hodgkin Lymphoma through trial conditions or approval indications mapped to it or to one of its descendant entities.
5 drugs · 58 active trials
6 drugs · 92 active trials
Outside the funnel: Phase not stated 2. "Withdrawn" = every approval record for the scope is withdrawn or superseded; "phase not stated" = trials exist but none states a phase.
Data updated 20 hours agoSource updated unknownrecomputed with the intelligence layer
Drugs
Most advanced stage first, then most active trials. Trial counts are interventional studies linking the drug (and, when a cancer is selected, the cancer).
| Drug | Stage | Max phase | Active | Recruiting | Phase 3 | Total trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Treosulfan | Phase 2 | Phase 2 | 1 | 1 | 0 | 3 | 0 | — | — | 2005-09 |
| Atezolizumab | Phase 2 | Phase 2 | 1 | 0 | 0 | 2 | 0 | — | — | Apr 14, 2017 |
| Tretinoin | Phase 2 | Phase 2 | 1 | 1 | 0 | 2 | 0 | — | — | Apr 1, 2020 |
| Blinatumomab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Jan 31, 2019 |
| Dostarlimab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 6, 2025 |
| Epirubicin | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Aug 26, 2019 |
| Isatuximab | Phase 2 | Phase 2 | 1 | 0 | 0 | 1 | 0 | — | — | Mar 31, 2023 |
| Tafasitamab | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Apr 28, 2023 |
| Temozolomide | Phase 2 | Phase 2 | 1 | 1 | 0 | 1 | 0 | — | — | Jul 1, 2021 |
| Alemtuzumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 10 | 0 | — | — | 2001-11 |
| Bortezomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 9 | 0 | — | — | 2004-11 |
| Romidepsin | Phase 2 | Phase 2 | 0 | 0 | 0 | 5 | 0 | — | — | Jul 17, 2013 |
| Tanespimycin | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 1999-10 |
| Temsirolimus | Phase 2 | Phase 2 | 0 | 0 | 0 | 4 | 0 | — | — | 2004-05 |
| Abexinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-11 |
| Bevacizumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2007-05 |
| Carfilzomib | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 2005-09 |
| Leucovorin | Phase 2 | Phase 2 | 0 | 0 | 0 | 3 | 0 | — | — | 1994-03 |
| Akt Inhibitor MK2206 | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-12 |
| Avelumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Mar 10, 2016 |
| Daratumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | Aug 2, 2012 |
| Hematopoietic Cell Transplantation | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2001-10 |
| Idelalisib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2011-09 |
| Ofatumumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2010-07 |
| Pacritinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2008-07 |
| Pralatrexate | Phase 2 | Phase 2 | 0 | 0 | 0 | 2 | 0 | — | — | 2007-05 |
| Acalabrutinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Feb 20, 2015 |
| Aldesleukin | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Apr 7, 2017 |
| Alvocidib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2005-12 |
| Cemiplimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 15, 2020 |
| Cladribine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jan 1, 2019 |
| Denosumab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 16, 2009 |
| Docetaxel | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 8, 2023 |
| Leuprolide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Meloxicam | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2013-10 |
| Mocetinostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2006-08 |
| Pexidartinib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 3, 2011 |
| Pomalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Aug 2, 2012 |
| Sugemalimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | May 22, 2018 |
| Tazemetostat | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Nov 13, 2017 |
| Thalidomide | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2003-07 |
| Thioguanine | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 1994-03 |
| Tipifarnib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Mar 24, 2004 |
| Toripalimab | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | Jul 25, 2023 |
| Veliparib | Phase 2 | Phase 2 | 0 | 0 | 0 | 1 | 0 | — | — | 2011-07 |
| Tagraxofusp | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Nov 11, 2022 |
| Zoledronic Acid | Phase 1 | Phase 1 | 1 | 1 | 0 | 1 | 0 | — | — | Feb 12, 2016 |
| Dasatinib | Phase 1 | Phase 1 | 0 | 0 | 0 | 4 | 0 | — | — | 2008-10 |
| Belinostat | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2006-03 |
| Nab-paclitaxel | Phase 1 | Phase 1 | 0 | 0 | 0 | 3 | 0 | — | — | 2013-09 |
Stages describe registered activity and ingested regulatory records, not efficacy. Only ingested jurisdictions (currently US and Canada) can place a drug at "approved"; trial phases are as registered by sponsors. Nothing here is a treatment recommendation.